These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 30919165)

  • 1. Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.
    Kothari G; Ost P; Cheung P; Blanchard P; Tree AC; van As NJ; Lo SS; Moghanaki D; Loblaw A; Siva S
    Curr Oncol Rep; 2019 Mar; 21(5):43. PubMed ID: 30919165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
    Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
    Parikh NR; Huiza C; Patel JS; Tsai S; Kalpage N; Thein M; Pitcher S; Lee SP; Inouye WS; Jordan ML; Sanati H; Jafari L; Bennett CJ; Gin GE; Kishan AU; Reiter RE; Lewis M; Sadeghi A; Aronson WJ; Garraway IP; Rettig MB; Nickols NG
    BMC Cancer; 2019 Apr; 19(1):291. PubMed ID: 30935383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy of oligometastatic prostate cancer: a systematic review.
    Rogowski P; Roach M; Schmidt-Hegemann NS; Trapp C; von Bestenbostel R; Shi R; Buchner A; Stief C; Belka C; Li M
    Radiat Oncol; 2021 Mar; 16(1):50. PubMed ID: 33750437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
    Kim J; Park JS; Ham WS
    Investig Clin Urol; 2017 Sep; 58(5):307-316. PubMed ID: 28868501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.
    Francolini G; Porreca A; Facchini G; Santini D; Bruni A; Simoni N; Trovò M; Osti MF; Fornarini G; Sisani M; Di Cataldo V; Detti B; Garlatti P; Bertini N; Serni S; Minervini A; Livi L
    Med Oncol; 2023 Dec; 41(1):39. PubMed ID: 38157111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A narrative review of oligometastatic prostate cancer-an evolving paradigm.
    Sritharan K; Rieu R; Tree A
    Ann Palliat Med; 2021 May; 10(5):5969-5987. PubMed ID: 33752437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.
    Supiot S; Rio E; Pacteau V; Mauboussin MH; Campion L; Pein F
    BMC Cancer; 2015 Sep; 15():646. PubMed ID: 26408012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
    Niazi T; Elakshar S; Stroian G
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of [
    Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
    Patel PH; Chaw CL; Tree AC; Sharabiani M; van As NJ
    World J Urol; 2019 Dec; 37(12):2615-2621. PubMed ID: 31346760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
    Schick U; Jorcano S; Nouet P; Rouzaud M; Vees H; Zilli T; Ratib O; Weber DC; Miralbell R
    Acta Oncol; 2013 Nov; 52(8):1622-8. PubMed ID: 23544357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].
    Rozet F; Hennequin C; Beuzeboc P; Mathieu R; Mongiat-Artus P; Beauval JB; Cormier L; Fromont-Hankard G; Ploussard G; Renard-Penna R; Brureau L; Méjean A
    Prog Urol; 2020; 30(8-9):430-438. PubMed ID: 32517891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radiotherapy in oligometastatic hormone-sensitive prostate cancer.
    Abdel-Aty H; James ND
    Curr Opin Urol; 2022 May; 32(3):277-282. PubMed ID: 35249966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligometastatic prostate cancer treatment.
    Rossetti S; Di Napoli M; Pisano C; C Cecere S; Tambaro R; Ventriglia J; Passarelli A; Iovane G; Feroce F; Lastoria S; Di Gennaro F; Muto P; Borzillo V; Di Franco R; Perdonà S; Quarto G; Pignata S
    Future Oncol; 2021 Oct; 17(29):3893-3899. PubMed ID: 34296622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
    Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
    Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.